Nasacort AQ (triamcinolone acetonide) Nasal Spray
Company: Phone-Poulenc Rorer
Approval Status: Approved October 1997
Treatment for: allergic rhinitis
Areas: Pediatrics/Neonatology; Pulmonary/Respiratory Diseases
Possible similar drugs: Nasacort AQ
General Information
Other Useful Resources
Nasacort (R) AQ (triamcinolone acetonide) has been approved by the U.S. Food and Drug Administration (FDA) for use the treatment of nasal symptoms of seasonal and perennial allergic rhinitis in children aged 6-11. Nasacort in currently available in the U.S. for adults and children aged 12 years and older.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
